Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Does age change how your body handles fisetin? new study aims to find out.

NCT ID NCT06796374

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at how the dietary supplement fisetin moves through the bodies of healthy young adults (18-30 years) compared to healthy older adults (65+). Eighty volunteers will take a single 500 mg dose of fisetin, either with or without food, and have their blood tested over 10 hours. The goal is simply to measure and compare fisetin levels in the blood, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fisetin (a dietary supplement)
What this could lead to
If successful, this study could help determine whether age affects how fisetin is absorbed and processed, guiding future research on its potential health benefits.
What could go wrong
This is an early-stage pharmacokinetic study in healthy volunteers, not designed to test any health outcomes. Results may not apply to people with medical conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * any sex * age between 18 and 30 years or ≥ 65 years * understands the study purpose and design * contractually capable and provides signed informed consent form * healthy condition or mild and/or well-treated forms of allergies, asthma, hypertension, and orthopedic diseases * a maximum of 3 chronically taken drugs Exclusion Criteria: * BMI \> 30 kg/m2 and \< 18 kg/m2 * body weight \< 48 kg * women in young cohort: known pregnancy or lactation period; positive urine pregnancy test at screening or kinetic visit * men: hemoglobin \< 8,3 mmol/l women: hemoglobin \< 7,3 mmol/l * elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin \> 2x ULN) * reduced renal function (eGFRMDRD \< 60 ml/min/1,7 m2) * QTcF \> 450 ms in screening ECG * psychiatric disease requiring recent or actual treatment * drug dependency at the time of visit * use of recreational drugs more than twice a week * any known hypersensitivity or allergic reactions to fisetin * history of severe hypersensitivity reactions and/or anaphylaxis * poor venous conditions that make it impossible to place a peripheral venous catheter and regularly draw blood through it * intake of drugs undergoing extensive metabolism via CYP1A2, CYP2D6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and/or Pgp and with narrow (monitoring-requiring) therapeutic range during the past seven days if the duration of intake was at least two days * intake of COMT-inhibitors during the past seven days if the duration of intake was at least two days * intake of drugs or dietary supplements containing fisetin within the two days before or during the kinetic visits * individuals who have eaten food with high fisetin content in the two days before the kinetic visits (e.g. strawberry, apple, persimmon, grape, mango, kiwi, peach, tomato, onion, lotus roots, kale, cucumber; processed products, e.g. wine)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pharmacokinetic study in healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Clinical Pharmacology, Institute of Pharmacology at the Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald

    RECRUITING

    Greifswald, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.